NASDAQ: QNTMQuantum Biopharma Ltd Stock
$19.16-0.16 (-0.83%)
Updated Jul 2, 2025
QNTM Price
$19.16
Fair Value Price
$3.29
Market Cap
$51.94M
52 Week Low
$2.70
52 Week High
$38.25
P/E
-1.73x
P/B
12.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.8
Operating Cash Flow
-$6M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QNTM Overview
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QNTM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
QNTM
Ranked#36 of 61
Ranked#36 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.94 | A | |
| $3.41 | A | |
| $8.37 | A |
Be the first to know about important QNTM news, forecast changes, insider trades & much more!
QNTM News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QNTM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNTM ($19.16) is overvalued by 481.59% relative to our estimate of its Fair Value price of $3.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QNTM ($19.16) is not significantly undervalued (481.59%) relative to our estimate of its Fair Value price of $3.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QNTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QNTM due diligence checks available for Premium users.
Valuation
QNTM fair value
Fair Value of QNTM stock based on Discounted Cash Flow (DCF)
Price
$19.16
Fair Value
$3.29
Overvalued by
481.59%
QNTM ($19.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QNTM ($19.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QNTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QNTM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.73x
Industry
4.27x
Market
31.27x
QNTM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.41x
Industry
2.23x
QNTM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNTM's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
QNTM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.3M
Liabilities
$7.2M
Debt to equity
1.8
QNTM's short-term liabilities ($7.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNTM's short-term assets ($7.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNTM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QNTM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
-$937.6k
Financing
$2.2M
QNTM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNTM vs Pharmaceutical Stocks
Quantum Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.